EUS-Guided Choledochoduodenostomy Versus ERCP for Primary Biliary Decompression in Distal Malignant Biliary Obstruction
NCT ID: NCT04898777
Last Updated: 2024-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2021-07-01
2024-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Pancreatobiliary cancers generally present with jaundice, weight loss, and anorexia with significant impact on quality of life, morbidity, and mortality.
The primary goal of diagnosis and management is curative resection but it's difficult due to local invasion and distant metastases at the time of clinical presentation. Biliary decompression helps to reduce symptoms and improve quality of life in patients with malignant biliary obstruction.
Endoscopically placed stents have become the standard of care for non-surgical biliary drainage due to their minimal invasiveness compared to percutaneous drainage.
The standard treatment of obstructive jaundice has been ERCP with biliary stent placement with high success rate in expert hands and low frequency of adverse events.
Endoscopic ultrasound-guided biliary drainage (EUS-BD) has been increasingly used in patients who underwent failed ERCP. EUS-BD can be performed in several ways, choledochoduodenostomy (CDS), hepaticogastrostomy (HGS), antegrade (AG) procedure, and rendezvous (RV) technique.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients with inclusion criteria will be recruited in the study by simple random sampling using sealed envelopes until fulfillment of needed sample size for both EUS-BD arm and ERCP-BD arm.
Study tools:
* Informed consent will be obtained from each participant sharing in the study.
* Throughout history taking, complete general examination and local abdominal examination.
* Laboratory investigations: CBC, Serum creatinine, Liver functions tests (AST, ALT and Serum Albumin), Alkaline phosphatase, Serum bilirubin and INR.
* ERCP-BD by papillary approach and EUS-BD by choledochoduodenostomy with transmural stent placement.
* All procedures will be performed under deep sedation or general anesthesia in the left lateral position.
* Procedural time is recorded.
* Technical success is considered after stent placement (expanded and patent) with good bile flow and drainage.
* Follow up:
* Lab investigations will be requested at 2 days, 2 and 4 weeks, 3 and 6 months after the procedure including:
CBC, S.Cr, S.Bil, AST, ALT, S.Alb, ALP and INR.
\- Early adverse events (within 48 hours after procedure) including: Pancreatitis, Cholangitis, Bleeding, Perforation and Peritonitis.
* Late adverse events include stent dysfunction either due to food impaction, tumor ingrowth or stent migration.
* Clinical success is considered at 2 weeks if total bilirubin is less than 50% of baseline and at 4 weeks if total bilirubin is less than 3mg/dL.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ERCP-BD
ERCP Biliary Drainage by papillary approach with stent placement.
Biliary drainage
Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
EUS-BD
Endoscopic Ultrasound guided Biliary Drainage by Choledochoduodenostomy with transmural stent placement.
Biliary drainage
Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biliary drainage
Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of locally advanced or metastatic pancreatic head mass on CT or magnetic resonance imaging of the abdomen
* Absence of duodenal obstruction.
* Elevated liver tests with serum bilirubin at least 3 times above the upper limit of normal (1.2 mg/dL).
* Histologic or cytologic diagnosis of malignancy.
* Accept sharing in the study.
Exclusion Criteria
* Pregnancy.
* Hilar biliary obstruction (as the main lesion or coexisting with distal obstruction).
* Presence of duodenal obstruction.
* Histologic or cytologic diagnosis of malignancy.
* Patients underwent previous intervention for biliary drainage.
* Previously failed biliary cannulation at ERCP.
* Prior biliary sphincterotomy or stent placement.
* Surgically altered anatomy or inability to access the major duodenal papilla.
* Patients unfit for anesthesia.
* Patients having uncorrectable coagulopathy or thrombocytopenia.
* History of allergy to radiocontrast agents.
* Refuse sharing in the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed M Gaheen, MSc.
Role: PRINCIPAL_INVESTIGATOR
Mansoura University
Ahmed Y Altonbary, MD
Role: STUDY_DIRECTOR
Mansoura University
Hazem H Alminshawy, Professor
Role: STUDY_DIRECTOR
Mansoura University
Ahmed G Deiab, A.Professor
Role: STUDY_DIRECTOR
Mansoura University
Magdy H Atwa, Professor
Role: STUDY_CHAIR
Mansoura University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Specialized Medical Hospital
Al Mansurah, Dakahlia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MD.21.03.437
Identifier Type: -
Identifier Source: org_study_id